ProQR Therapeutics

ProQR Therapeutics EBIT

The EBIT of ProQR Therapeutics (PRQR) as of Nov 17, 2026 is -42.15 M EUR. In the previous year, EBIT was -30.47 M EUR — a change of 38.34% (lower).

EBIT

-42.15 MEUR

YoY

38.34%

Last updated:

In 2025, ProQR Therapeutics's EBIT was -42.15 M EUR, a 38.34% increase from the -30.47 M EUR EBIT recorded in the previous year.

The ProQR Therapeutics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2024
-30.47 M EUR
Jan 1, 2025
-42.15 M EUR
Jan 1, 2026 (e)
-43.79 M EUR
Jan 1, 2027 (e)
-55.76 M EUR
Jan 1, 2028 (e)
-32.57 M EUR
Jan 1, 2029 (e)
-43.71 M EUR
Jan 1, 2030 (e)
-5.26 M EUR
Jan 1, 2031 (e)
0.00 EUR
The ProQR Therapeutics EBIT history
YEAREBITYoY
est0.00EUR-100.00%
est-5.26 MEUR-87.96%
est-43.71 MEUR+34.19%
est-32.57 MEUR-41.58%
est-55.76 MEUR+27.33%
est-43.79 MEUR+3.88%
-42.15 MEUR+38.34%
-30.47 MEUR-4.35%
-31.86 MEUR-51.11%
-65.16 MEUR+13.89%
-57.21 MEUR+35.03%
-42.37 MEUR-26.25%
-57.45 MEUR+58.28%
-36.29 MEUR-10.38%
-40.50 MEUR+2.34%
-39.57 MEUR+46.55%
-27.00 MEUR+64.04%
-16.46 MEUR+408.21%
-3.24 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProQR Therapeutics Revenue

ProQR Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
18.91 M EUR
-30.47 M EUR
-27.76 M EUR
Jan 1, 2025
15.28 M EUR
-42.15 M EUR
-40.52 M EUR
Jan 1, 2026 (e)
16.87 M EUR
-43.79 M EUR
-44.75 M EUR
Jan 1, 2027 (e)
19.71 M EUR
-55.76 M EUR
-52.02 M EUR
Jan 1, 2028 (e)
49.83 M EUR
-32.57 M EUR
-29.59 M EUR
Jan 1, 2029 (e)
56.07 M EUR
-43.71 M EUR
-44.77 M EUR
Jan 1, 2030 (e)
155.39 M EUR
-5.26 M EUR
-6.31 M EUR
Jan 1, 2031 (e)
245.29 M EUR
0.00 EUR
0.00 EUR

ProQR Therapeutics Margins

ProQR Therapeutics stock margins

The ProQR Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ProQR Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ProQR Therapeutics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
100.00 %
-161.18 %
-146.86 %
Jan 1, 2025
83.01 %
-275.91 %
-265.21 %
Jan 1, 2026 (e)
83.01 %
-259.52 %
-265.23 %
Jan 1, 2027 (e)
83.01 %
-282.83 %
-263.89 %
Jan 1, 2028 (e)
83.01 %
-65.37 %
-59.39 %
Jan 1, 2029 (e)
83.01 %
-77.96 %
-79.84 %
Jan 1, 2030 (e)
83.01 %
-3.39 %
-4.06 %
Jan 1, 2031 (e)
83.01 %
0.00 %
0.00 %

ProQR Therapeutics Stock analysis

What does ProQR Therapeutics do? ProQR Therapeutics NV is a Dutch biotechnology company focused on the production of RNA medications for the treatment of genetic diseases. The company was founded in 2012 by Daniel de Boer, Dinko Valerio, and Gerard Platenburg. Since its IPO in 2014, the company has been listed on the NASDAQ. ProQR utilizes a technology called RNA therapeutics, which consists of RNA and offers an alternative treatment method, especially for genetic diseases. Thanks to RNA medications, it is possible to repair faulty mRNA sequences and correct gene expression. This can help fight diseases caused by defective genes, including previously considered incurable diseases. The company works closely with researchers and doctors to develop innovative therapies that truly help patients. Their focus is on diseases that have not been treatable or have a low cure rate in conventional medicine. Diseases that ProQR deals with include cystic fibrosis, inherited retinal diseases, inherited amyloidosis, cancer treatment, and rare genetic diseases. Cystic fibrosis, also known as CF, is one of the most well-known diseases that the company treats. This disease mainly affects children and young adults. Cystic fibrosis is caused by a mutation of the CFTR gene, which disrupts the salt-water balance in the lungs and pancreas. ProQR has developed an RNA therapy called QR-010, which aims to repair the function of the CFTR gene and alleviate the lungs and pancreas. ProQR works closely with clinics to treat patients with this therapy. The company also has RNA medications in the pipeline that help with inherited retinal diseases. One of these diseases is retinitis pigmentosa, which kills the retina and can lead to blindness. ProQR is developing a drug called QR-421a, which is intended to improve vision. The company hopes that the drug will soon be on the market and help patients with retinitis pigmentosa. ProQR is also working on the development of RNA medications to combat rare genetic diseases. This includes the treatment of amyloidosis, a disease in which abnormal proteins accumulate in the body and cause damage. RNA medications could help interrupt the production of abnormal proteins, thereby minimizing damage in the body. ProQR is also working on RNA therapy for cancer. The company focuses on developing medications to combat genetically caused cancer, particularly tumors caused by the loss of heterozygosity (LOH). These tumors can be treated with RNA medications targeting correct gene expression. ProQR Therapeutics NV has had an impressive success story in recent years. The company holds several patents on RNA therapeutics and has built an excellent reputation as a biotechnology company. ProQR's RNA therapies have the potential to successfully treat many genetic diseases that are not possible with conventional medicine. They represent a source of hope for many patients, especially those with cystic fibrosis. The company will continue to develop new RNA therapeutics to treat rare genetic diseases that have been difficult to fight. ProQR Therapeutics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing ProQR Therapeutics's EBIT

ProQR Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of ProQR Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

ProQR Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in ProQR Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about ProQR Therapeutics stock

EBIT of ProQR Therapeutics is -42.15 M EUR in 2025.

EBIT of ProQR Therapeutics changed from -30.47 M EUR to -42.15 M EUR, representing a 38.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT ProQR Therapeutics since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's ProQR Therapeutics historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ProQR Therapeutics

All Key Metrics — ProQR Therapeutics